Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson J C, Ross F, Combaret V, Delattre O, Feuerstein B G, Plantaz D
Department of Medical Genetics, Ghent University Hospital, Belgium.
Med Pediatr Oncol. 2001 Jan;36(1):5-10. doi: 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E.
Analysis of comparative genomic hybridization (CGH) data of 120 tumors from four different studies, and data of 84 previously unpublishied tumors, allowed delineation of at least six different genetic subsets of neuroblastomas.
A small number of tumors show no detectable imballances. A second group of tumors presents with gains and losses of whole chromosomes and is found predominantly in prognostically favorable stage 1 and 2 tumors. The remaining groups are characterized by the presence of partial chromosome imbalances, and are found mostly in stage 3, 4, and 4S tumors. The third group shows 17q gain without 11q loss, 1p loss, or MYCN amplification (MNA). The fourth group has 1p deletion or MNA, and finally, a fifth group shows 11q loss without 1p deletion or MNA, and is found mainly in stage 4 tumors. The latter group is significantly associated with losses of 3p, 4p, and 14q.
对来自四项不同研究的120个肿瘤的比较基因组杂交（CGH）数据以及84个先前未发表的肿瘤数据进行分析，从而确定了至少六个不同的神经母细胞瘤遗传亚组。
少数肿瘤未检测到失衡。第二组肿瘤表现为整条染色体的增减，主要见于预后良好的1期和2期肿瘤。其余组的特征是存在部分染色体失衡，主要见于3期、4期和4S期肿瘤。第三组显示17q增益，无11q缺失、1p缺失或MYCN扩增（MNA）。第四组有1p缺失或MNA，最后，第五组显示11q缺失，无1p缺失或MNA，主要见于4期肿瘤。后一组与3p、4p和14q缺失显著相关。
